Technologies

4Ts Game was born in ITD in 2017 to indicate a board game for teacher training, which aims to develop skills in designing collaborative learning activities. The game was originally conceived as a 'tangible' game, consisting of a board and 4 decks of paper cards which contain inputs that guide the teachers/players' design process. Subsequently the game evolved and was developed in its digital version. In this version, developed in Unity and with an underlying knowledge base in Prolog, the game is able to provide feedback to teachers regarding the design/game choices made.

Time-correlated single photon counting (TCSPC) is regarded as the “gold-standard” method for fluorescence lifetime measurements. However, TCSPC requires using highly sensitive detectors, not suitable for measurements under bright light conditions, thereby making the use impractical in clinical settings. The invention described here solves this problem by synchronizing the fluorescence detection with an external light source.

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The final technology will add polarimetric capability to imaging cameras in the NUV/optical, providing simultaneous measurements of the different polarization states of the light. This will be obtained by the development of an innovative coating based on nanostructured emissive materials sensitive to the polarization of the incident light. A  double layer film of two organic systems will be coupled to image detectors so that the two polarization components of the incoming light are converted into two different colors.

The assessment of bio-humoral markers beyond clinical evaluation would allow a more comprehensive pheno/endotyping of patients affected by chronic inflammatory diseases. Therapy personalization would require a profile of the mediators that are relevant in the disease pathogenesis and that well correlate with prognosis. Currently, the measurement of multiple biomarkers is not included in patient evaluation because it has high costs,  requires centralized laboratories, experienced personnel and bulky equipment and is time-consuming.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

Our innovative proposal involves an educational robotics training program, resulting from an experimental research that combines traditional educational approaches with the utilization of robotics. Specifically, the educational robot Thymio, developed by EPFL, serves as a facilitator in the learning process to enhance School Readiness.

Inert biomedical devices with modular load-bearing function designed with peculiar multi-domain composite microstructures. The reference compositional system is Zirconia-Alumina with a prevailing overall composition of customizable zirconia or alumina. Examples of devices are 3D structures consisting of parts with differentiated functional properties, due to different composition/microstructure/architecture, and further functionalizable ex-post to favor and improve the stabilization of the implantation by newly formed bone in superior quantity and quality.

We developed a procedure aimed at simultaneously treating thousands of C.elegans model organisms, from eggs to old adult, in liquid, in 96- or 384-well plates. This procedure can be used to perform drug and toxicological screening of millions of compounds, in very small volumes and on millions of animals. Thanks to easy handling, semi-automatic analysis can be performed using plate readers or High Content Screening instruments.

Our idea come from the improving of the traceability technique in agro-food fisheries industries through the application of omics technologies in microbiota studies.  These latter would be capable of exploiting the huge pool of biological molecules contained in fishery resources (e.g. nucleic acids, proteins, metabolites) and use them as a powerful tools for the identification and reconstruction of fishery history, from the sea to the table.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

Mergers e Acquisitions represent important forms of business deals because of the volumes involved in the transactions and the role of the innovation activity of companies. By considering the patent activity of about one thousand companies, we develop a method to predict future acquisitions by assuming that companies deal more frequently with technologically related ones.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.